Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression (original) (raw)
Related papers
Plasma leptin and adiponectin in COPD exacerbations: Associations with inflammatory biomarkers
Respiratory Medicine, 2010
Background: Various systemic inflammatory markers have been evaluated for their value in acute exacerbations of chronic obstructive pulmonary disease (COPD). Leptin and adiponectin have been linked to acute exacerbations and stable COPD. Objectives: To assess plasma leptin, adiponectin and their ratio in acute exacerbations of COPD and to study possible associations with inflammatory biomarkers. Methods: Plasma leptin, adiponectin and their ratio (L/A) and serum biomarkers of systemic inflammation C-reactive protein (CRP), Tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6) were assessed at three time points (admission, resolution and stable phase e 8 weeks after resolution) in a selected cohort of 63 COPD patients hospitalized for acute exacerbations. Subjects with comorbidities related to adipose tissue hormones were meticulously excluded. Measurements and main results: All systemic inflammatory biomarkers, leptin and L/A ratio were elevated during admission compared to resolution and stable phase (mean L/A ratio 2.6 vs. 1.57 vs. 1.22, respectively; p < 0.0001), whereas adiponectin was elevated at resolution compared to admission. Log leptin, adiponectin and L/A ratio were significantly associated with variables of systemic inflammation, after proper adjustments, both on admission and in stable condition. In stepwise multiple linear regression models, IL-6 and TNF-a present the most significant associations with leptin, adiponectin and their ratio.
Annals of the American Thoracic Society, 2014
The rate of annual change in FEV1 is highly variable among patients with chronic obstructive pulmonary disease (COPD). Reliable blood biomarkers are needed to predict prognosis. To explore plasma biomarkers associated with an annual change in FEV1 in patients with COPD. Plasma samples of 261 subjects, all Japanese, with COPD from the 5-year Hokkaido COPD cohort study were analyzed as a hypothesis-generating cohort, and the results were validated using data of 226 subjects with and 268 subjects without airflow limitation, mainly white, from the 4-year COPD Quantification by Computed Tomography, Biomarkers, and Quality of Life (CBQ) study conducted in Denmark. The plasma samples were measured using Human CardiovascularMAP (Myriad RBM, Austin, TX), which could analyze 50 biomarkers potentially linked with inflammatory, metabolic, and tissue remodeling pathways, and single ELISAs were used to confirm the results. Higher plasma adiponectin levels and a lower leptin/adiponectin ratio at e...
Nutrients, 2013
Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease which may be complicated by development of co-morbidities including metabolic disorders. Metabolic disorders commonly associated with this disease contribute to lung function impairment and mortality. Systemic inflammation appears to be a major factor linking COPD to metabolic alterations. Adipose tissue seems to interfere with systemic inflammation in COPD patients by producing a large number of proteins, known as "adipokines", involved in various processes such as metabolism, immunity and inflammation. There is evidence that adiponectin is an important modulator of inflammatory processes
Possible Role of Serum Leptin as Biomarker in COPD
Folia Medica, 2019
Leptin is one of the adipokines shown to exert a significant effect in respiratory diseases, including chronic obstructive pulmonary disease (COPD).The aim of the present study was to evaluate the possible role of serum leptin as biomarker in COPD.The serum leptin levels were assessed in 58 patents with stable COPD and 21 controls applying ELISA method.The leptin levels were higher, although not significantly, in COPD patients than in controls (221.52±24.28(SE) vs. 165.04±26.01 pg/ml, p=0.197). This tendency turned out significant when only females were compared (414.60±60.63 vs. 219.40±44.15 pg/ml, p=0.038). The levels of leptin were highly dependent on the BMI both in COPD patients (p<0.001) and in controls (p=0.024): they were the highest in obese individuals and decreased with reducing the BMI.In the COPD group, women had significantly higher leptin levels than men (p<0.0001) independent of the BMI. The non-smoking patients had significantly higher leptin levels than ex-sm...
Life
Chronic obstructive pulmonary disease (COPD) is characterized by respiratory symptoms and non-reversible airflow limitation with recurrent episodes of acute exacerbations. The concurrent presence of bronchiectasis in patients with COPD is associated with reduced respiratory function as well as increased exacerbation risk. Adiponectin is a promising biomarker in COPD, as greater high molecular weight (HMW) oligomer levels have been observed among COPD patients. Here, we investigate adiponectin levels in two groups of COPD patients characterized by the presence or absence of bronchiectasis (BCO), comparing both groups to healthy controls. We evaluated serum adiponectin levels in COPD patients, those with BCO, and healthy subjects and characterized the pattern of circulating adiponectin oligomers. We found that forced volume capacity % (FVC%) and forced expiratory volume % (FEV1%) were lower for BCO patients than for COPD patients. COPD patients had higher levels of adiponectin and its...
Respiratory Medicine, 2014
Objectives: Adipokines are protein mediators first described as products of adipose tissue regulating energy metabolism and appetite. Recently, adipokines have also been found to modulate inflammation and smooth muscle cell responses. Therefore we investigated the association of two adipokines, adiponectin and leptin, with the degree of emphysema, pulmonary function, symptoms and glucocorticoid responsiveness in patients with COPD. Methods: Plasma adiponectin and leptin levels, spirometry, body plethysmography and symptoms were measured in 43 male COPD patients with smoking history ! 20 pack-years, post bronchodilator FEV 1 /FVC < 0.7 and pulmonary emphysema on HRCT. The measurements were repeated in a subgroup of patients after 4 weeks' treatment with inhaled fluticasone. Results: In patients with COPD, plasma adiponectin levels correlated positively with airway resistance (Raw) (r Z 0.362, p Z 0.019) and functional residual capacity (FRC) (r Z 0.355, p Z 0.046). Furthermore, the baseline adiponectin concentration correlated negatively with Respiratory Medicine (2014) 108, 122e128 the fluticasone induced changes in St George's Respiratory questionnaire (SGRQ) symptom score (r Z À0.413, p Z 0.040) and in FRC % pred (r Z À0.428, p Z 0.003), i.e. a higher baseline plasma adiponectin level was associated with more pronounced alleviation of symptoms and dynamic hyperinflation. Plasma leptin levels were not related to the measures of lung function, symptoms or glucocorticoid responsiveness. Conclusions: Plasma adiponectin levels were associated with peripheral airway obstruction and dynamic hyperinflation in patients with COPD. A higher adiponectin level predicted more favourable relief of symptoms and hyperinflation during glucocorticoid treatment. Adiponectin may have a role in the COPD pathogenesis; it may also be a biomarker of disease severity and treatment responses in this disease. ª
Physiological Research, 2012
Increases in resting energy expenditure (REE) likely contribute to weight loss in various chronic diseases. In chronic obstructive pulmonary disease (COPD), relationships between the ventilatory impairment and increased REE, and between disturbances in adipokines and weight loss were previously described. Therefore, we investigated serum levels and adipose tissue expression of leptin and adiponectin, and their relationships to REE in patients with COPD. In 44 patients with stable COPD (38 male; age 62.3±7.2 years), REE was assessed using indirect calorimetry. Subcutaneous adipose tissue samples were analyzed using real-time PCR. From underweight [n=9; body mass index (BMI) <20.0 kg.m−2], to normal weight-overweight (n=24, BMI=20.0-29.9 kg.m−2) and obese patients (n=11; BMI≥30 kg.m−2), REE adjusted for body weight decreased (32.9±6.1 vs. 26.2±5.8 vs. 23.9±6.6 kcal.kg−1.24 h−1, p=0.006), serum levels and adipose tissue expression of leptin increased (p<0.001 for both), and serum...
Objective: The aim of this study was to assess the level of serum leptin hormone in chronic obstructive pulmonary disease patients during acute exacerbation and in stable conditions and also, to determine if these changes correlate with changes in the ventilatory functions. Methods: Sixty cases were included in this prospective study (40 COPD patients and 20 age related smokers without symptoms or signs of COPD and within normal pulmonary functions as a control). Patients and control were divided according to their BMI into obese (BMI P 30) and non-obese (BMI = 18.5–25). Subjects were submitted to full history taking, thorough physical examination, plain chest X-ray, complete blood count, erythrocyte sedimentation rate, liver and kidney functions, fasting and post prandial blood sugar, ventilatory functions, and serum leptin level measurement. Results: Serum leptin level (ng/ml) was significantly higher (P < 0.001) in stable obese COPD (mean ±SD = 23.85± 4.47) patients than obese controls (mean ± SD= 20.9 ± 2.7) and stable non-obese COPD (mean ± SD= 5.63 ± 1.05) and stable non-obese COPD cases had significantly higher (P <0.05) serum leptin level than non-obese controls (mean ± SD= 6.53 ± 1.19). Serum leptin level was significantly higher (P< 0.001) in obese COPD cases during exacerbation (mean ±SD = 67.59± 9.8) than in non-obese COPD cases during exacerbation(mean±SD=18.14±4.15). Significant positive correlation between serum leptin and BMI (kg/m2) of different groups (P <0.01) [obese control (r = 0.945), non-obese control (r =0.970), obese COPD in exacerbation (r = 0.812), obese COPD in stable state (r = 0.774), non-obese COPD exacerbation (r =0.876) and non-obese COPD in stable state (r = 0.799)]. Conclusion: Serum leptin hormone level (ng/ml) was significantly higher in obese COPD cases than in controls and non-obese cases and during exacerbation than in stability which indicates that leptin plays a role in the systemic inflammatory process. Serum leptin hormone level positively correlated with BMI (kg/m2).
The role of adipokines in the pathogenesis and course of selected respiratory diseases
Endokrynologia Polska, 2019
Adipose tissue is also a secretory organ producing active substances called adipokines. Some of them (apelin, resistin, adiponectin, leptin, chemerin, or visfatin) may play a role in the pathogenesis and course of respiratory diseases, e.g. COPD, asthma, pulmonary hypertension, or lung cancer. There are limited and conflicting data on the role of adipokines in asthma. It has been confirmed, however, that visfatin and leptin can be markers of inflammation in COPD. Elevated concentrations of leptin and resistin play a pro-inflammatory role in the development of cancer cachexia. The role of adipokines has also been demonstrated in pulmonary hypertension, and the apelinadiponectin axis disruption may exacerbate pulmonary hypertension.